A detailed history of Eventide Asset Management, LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Eventide Asset Management, LLC holds 919,635 shares of COGT stock, worth $8.26 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
919,635
Previous 1,398,992 34.26%
Holding current value
$8.26 Million
Previous $11.8 Million 15.78%
% of portfolio
0.18%
Previous 0.21%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.24 - $11.48 $3.95 Million - $5.5 Million
-479,357 Reduced 34.26%
919,635 $9.93 Million
Q2 2024

Aug 13, 2024

BUY
$6.01 - $9.04 $8.41 Million - $12.6 Million
1,398,992 New
1,398,992 $11.8 Million
Q4 2023

Feb 14, 2024

BUY
$4.06 - $10.08 $336,850 - $836,317
82,968 Added 3.86%
2,232,968 $13.1 Million
Q3 2023

Nov 14, 2023

SELL
$9.69 - $13.34 $12.5 Million - $17.2 Million
-1,290,796 Reduced 37.51%
2,150,000 $21 Million
Q2 2023

Aug 15, 2023

BUY
$9.85 - $13.24 $8.38 Million - $11.3 Million
851,018 Added 32.86%
3,440,796 $40.7 Million
Q4 2022

Feb 13, 2023

SELL
$10.65 - $14.84 $2.89 Million - $4.02 Million
-271,114 Reduced 9.48%
2,589,778 $29.9 Million
Q3 2022

Nov 14, 2022

SELL
$9.39 - $16.99 $21 Million - $38 Million
-2,234,108 Reduced 43.85%
2,860,892 $42.7 Million
Q2 2022

Aug 15, 2022

BUY
$3.92 - $9.73 $4.68 Million - $11.6 Million
1,195,000 Added 30.64%
5,095,000 $46 Million
Q1 2022

May 16, 2022

BUY
$5.31 - $8.7 $2.04 Million - $3.35 Million
385,091 Added 10.96%
3,900,000 $29.2 Million
Q4 2021

Feb 14, 2022

BUY
$7.51 - $10.81 $26.4 Million - $38 Million
3,514,909 New
3,514,909 $30.2 Million

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $591M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track This Portfolio

Track Eventide Asset Management, LLC Portfolio

Follow Eventide Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.